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Abstract A clone (P2) coding for an allergen of Parietaria 
judaica (Pj) pollen has been isolated and sequenced from a cDNA 
library in lambda ZAP using a pool of 23 sera from Pj-allergic 
patients. The clone contained an insert of 622 nucleotides with an 
open reading frame of 133 amino acids (aa) and a putative signal 
peptide of 31 aa giving a deduced mature processed protein of 
102 aa with a molecular mass of 11344 Da. The expressed 
recombinant protein, named rPar j 2.0101, was a major allergen 
since it reacted with IgE of 82% (23128) of the sera of Pj-allergic 
subjects analyzed. It was shown to be a new allergen since (i) the 
amino acid sequence homology with the already reported 
recombinant allergen Par j 1.0101 was 45% and (ii) there was 
no cross-inhibition between rPar j 2.0101 and rPar j 1.0101. In 
addition, rPar j 2.0101 inhibited 35% of the specific IgE for 10- 
14 kDa native allergens and preincubation of sera from Pj- 
allergic patients with both rPar j 2.0101 and rPar j 1.0101 fully 
abolished the IgE recognition of the 10-14 kDa native allergen 
region, suggesting that these two allergens contributed to the 
region. 
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1. Introduction 
Parietaria judaica pollen is the main cause of allergy in the 
Mediterranean area and an epidemiological study carried out 
~n allergic patients in Sicily showed that up to 50% reacted to 
Fj pollen extract [1,2]. The allergenic molecules contained in 
l ie  pollen are usually a complex mixture of various proteins 
differing in either specific IgE binding or biochemical proper- 
tes. The Pj pollen extract contains at least nine allergens 
t~aving different molecular weights and IgE-binding specificity. 
r'he molecular mass ranges between 10 and 80 kDa [1 5] and 
t ae allergens found on the 10-14 kDa region reacted with the 
lgE of 95% of the sera from Pj-allergic patients tested, sug- 
~'esting that major allergens are present in this region [6]. In 
~rder to plan a diagnostic and therapeutic approach to the 
t,:llergic reaction, a preliminary step is to purify and to char- 
t cterize each major allergen and a powerful tool towards this 
1 irget is the molecular cloning of the allergens [7,8]. We have 
~,lready cloned and characterized one of the major allergens of 
~Corresponding author. Fax: (39) (91) 6165665. 
.tbbreviations: Pj, Parietariajudaica; IgE, immunoglobulin E; RAST, 
~adioallergosorbent test; cDNA, DNA complementary to mRNA; 
t:'CR, polymerase chain reaction. 
IMBL data bank accession umber P2:X95865. 
the P. judaica pollen that belongs to the 10-14 kDa region [9], 
Par j 1.0101, a protein of 139 amino acids and a predicted 
molecular mass of 14509 Da. In this paper, we report the 
cloning, sequence, expression and allergenic activity of a 
new major allergen of Pj pollen named Par j 2.0101 according 
to the suggested allergen nomenclature [10]. 
2. Materials and methods 
2.1. Total and poly(A) + RNA preparation 
Total and poly(A) + RNA extracted from Pj flowers collected in 
Palermo, Italy, was prepared as described [9]. 
2.2. cDNA library screening and cDNA sequencing 
Double-stranded cDNA was synthesized from mRNA by using 
oligo(dT) primers and cloned into the EcoRI and XhoI sites of the 
lambda ZAP expression vector, according to the Stratagene cDNA 
cloning kit (Stratagene, USA). 
6× 105 plaques were immunologically screened by using a pool of 
sera (n = 23) diluted 1:5 in PBS-containing 0.25% BSA, obtained from 
patients allergic to Pj pollen. Positive clones were identified by using 
12~l-labelled anti-human IgE. 
The nucleotide sequence of the cDNA insert was determined on 
both strands of the PBK-CMV plasmid vector by the dideoxy chain 
termination method using a Sequenase Kit (Amersham, USA). 
2.3. Cloning in pMALc2 
The oligonucleotides were synthesized by Pharmacia Biotech. Pri- 
mers for PCR were (lower-case letters indicate the restriction enzyme 
cloning site; upper-case l tters denote the coding sequence): (oligo 1) 
5' ccggaattcGAGGCTTGCGGGAAAGTGGTGCAGGAT 3' (oligo 
2) 5' gtgtctagaATAGTAACCTCTGAAAATAGTACTTTGG 3'.1 ng 
of the P2 clone was subjected to 30 cycles of PCR under the following 
conditions: 94°C 30 s, 52°C 30 s, 72°C 30 s. 
The PCR product was fractionated on 1.8% agarose gel and after 
several steps of purification, digested with EcoRI and XbaI restriction 
enzymes. The fragments were cloned in the EcoRI/XbaI sites of the 
pMALc2 vector (Biolabs, UK). Recombinant clones were sequenced 
using the dideoxynucleotide chain termination method. 
2.4. Preparation of the recombinant allergens 
The recombinant clones were grown to 0.5~0.60D600 in LB broth 
and induced for 2 h with 0.3 mM isopropylthio-[~-D-galactoside 
(IPTG). The cells were harvested by centrifugation (4000 rpm/20 
min) and stored frozen. After thawing, the pellet was dissolved in 
sodium phosphate buffer (10 mM Na phosphate, pH 7.2; 200 mM 
NaC1, 1 mM EDTA, 1 mM NAN3) and lysed by sonication using a 
Heat-System-Ultrasonic, In /W-385. The cell debris was then removed 
by centrifugation (9000 rpm/30 rain) and the supernatant was diluted 
1:20 with 10 mM EDTA and concentrated up to 2 mg/ml of total 
proteins by using a centriprep concentrator (Amicon) with a molecu- 
lar mass cut-off of 10 kDa. The concentration of the recombinant 
allergens was detected by densitometry analysis of SDS-PAGE gels 
stained with Coomassie Brilliant Blue. 
2.5. Western blot analysis 
Protein samples were denatured under reducing conditions by boil- 
ing for 5 min in 50 mM Tris-HC1 pH 6.8, 1% SDS, 2% ~-mercap- 
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M R T V S M A A 
P. j 2. 0101 acagtc tcagacacacccct t t tccaaact tccaacATGAGGACCGTGTCGATGGCGGCA 
1 60 
L V V I A A A L A W T S S A E P A P A P 
CTCGTTGTGATCGCGGCGGCGCTCGCGT GGACATCTTCGGCTGAGCCGGCTCCAGCCCCG 
120 
A P G E E A C G K V V Q D I M P C L H F 
GCC C CAGGAGAG GAGGCTTGCGGGAAAGT G GT GCAGGATATAAT GCC GT GCCT GCATT T C 
180 
V K G E E K E P S K E C C S G T K K L S 
GT GAAGGGGGAGGAGAAGGAGCC GTC GAAGGAGT GCT GCAGC GGCAC GAAGAAGCT GAGC 
240 
E E V K T T E Q K R E A C K C I V R A T 
GAGGAGGT GAAGAC GAC G GAGCAGAAGAGGGAG CCT GCAAGT GCATAGT GCGCGC CAC G 
30O 
K G I S G I K N E L V A E V P K K C D I 
AAGGGCAT CT C CGGTAT CA~T GAACT T GT CGC CGAGGT CC CCAAGAAGT GCGATAT T 
360 
K T T L P P I T A D F D C S K I Q S T I 
AAGACCACTCTCCCGCCCATCACCGCCGACTTCGACTGCTCCAAGATCCAAAGTACTATT 
420 
F R G Y Y * 
TTCAGAGGTTACTATt  agcaagt  tagagagcgt  t tt ct c t taat  t t ct aagtgtggggaa 
480 
c taaaaataaat ta tggcatgt  tacgt t  c ta taaggccatgt t  c t t ta ta tgaataatga  
540 
tg ta t ta tgtgt  g taat tgatat tgatgtaataatgt taacaatacgatggaataatgt t  
6O0 
aacaatatgaaat tgctactc taaaaaaaaaaaaaaaaa  3 ' 
Fig. 1. Nucleotide and deduced amino acid sequence of the cDNA coding for the rPar j 2.0101 allergenic protein. Numbers in the right margin 
refer to the position of the nucleotides. The deduced amino acid sequence is shown using the single-letter code above the corresponding nucleo- 
tide triplet. The primers used for PCR are underlined. 
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34 50 
Par j IB G P X G K V V X l l  IMP  C L K F V K G  
I I I I I I I I i I I I I 
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Fig. 2. (A) Comparison between the rPar j 2.0101 and rPar j 1.0101 allergens, the putative signal peptide is underlined. (B) Comparison be- 
tween the rPar j 2.0101 and two native isoforms of Parietaria allergens, i.e. Par 1A and Par 1B [5]. The dash indicates identity. Numbers refer 
to the amino acid sequence position of the Par j 2.0101 allergen. 
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toethanol, 0.01% bromophenol blue and separated by SDS-PAGE. 
The proteins were therefore electroblotted to Immobilon-P mem- 
branes (Millipore, USA) and then blocked for 3 h at room tempera- 
ture in PBS supplemented with 3% BSA, 0.5% Tween and 0.02% 
NaN3 and washed three times with PBS containing 0.1% (v/v) of 
lween 20. Inhibition was carried out by adding to the diluted serum 
p,~ol increasing amounts of recombinant proteins for 3 h at room 
tumperature. The filters were then incubated overnight at room tem- 
perature with the serum pool previously absorbed. After a washing 
s ep, the filters were incubated for 1 h at room temperature with 
E~rseradish peroxidase (HRP)-conjugated rabbit anti-human IgE 
(',;igma, St. Louis, MO). The final reaction was developed with an 
ICL detection system (Amersham, USA). The signal intensity was 
t teasured by using a Biorad densitometer (model GS-670). 
5. Results and discussion 
Ten clones capable of interacting with human IgE were 
i+olated after screening of a lambda ZAP cDNA library using 
pool of 23 sera of patients allergic to P. judaica pollen. 
,',even clones were still capable of binding human IgE after 
~everal steps of purification. The purified clones gave no IgE 
binding when tested with sera (n = 5) of subjects not allergic to 
l'j pollen. The sequence of the clones was then analyzed and 
,,ne clone, named P2, was found to share an independent full- 
i.zngth cDNA. Sequence analysis of the P2 clone showed a 622 
~ ucleotide insert with an open reading frame of 399 bp termi- 
~ ating with a TAG stop codon (Fig. 1). The cDNA contained 
, 36 nucleotide leader sequence and 184 nucleotide untrans- 
'~ tted region with a canonical polyadenylation site and poly(A) 
i ail. The cDNA insert encoded a protein of 133 aa with a 
,:educed molecular mass of 14 105 Da. The hydrophobicity 
,rofile of the protein showed, in the amino-terminal region, 
putative signal peptide of 31 aa specific for eukaryotic gly- 
, osylated proteins, giving a deduced mature processed protein 
,f 102 aa with a molecular mass of 11 344 Da. 
The recombinant allergenic protein named rPar j 2.0101 
howed an homology of 45% with the aa sequence of the 
KDa 1 2 3 4 
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!Zig. 3. Western blotting analysis. The recombinant allergen Par j 
',.0101 (1 lag/lane) was run on 10% SDS-PAGE and immunoblotted 
ts described in Section 2. Molecular mass markers (Biorad, USA) 
xpressed in kDa are shown on the left. Lanes: 1, induced rPar j 
',.0101 incubated with a pool of sera from Pj-allergic patients; 2, in- 
luced rPar j 2.0101 incubated with a pool of sera from non-allergic 
,ubjects; 3, non-induced rPar j 2.0101 incubated with a pool of sera 
t'rom Pj+allergic patients; 4, induced pMAL-c2 incubated with a 
pool of sera from Pj-allergic patients. The pool of sera was diluted 
1:5 with PBS-0.25% BSA. Specific IgE binding was detected with 
the HRP-conjugated anti-human IgE and ECL system. 
Par j 1.0101 
297 
Parj 2.0101 
Parj 2.0101 
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Fig. 4. Slot-blot inhibition. The recombinant allergens Par j 2.0101 
and Par j 1.0101 were spotted (l [.tg/slot) on nitrocellulose. The pool 
of sera from Pj-allergic patients diluted 1:5 was preincubated for 3 h 
at room temperature, with increasing amounts of recombinant al- 
lergen (1, 10, 50 lag/ml). U: pool of sera diluted 1:5 and preincub- 
ated with buffer alone as a control. Specific IgE binding was de- 
tected as reported in Fig. 3. 
recombinant allergen Par j 1.0101 already reported [9] (Fig. 
2A). In addition, from amino acids E32 to G51, rPar j  2.0101 
showed significant homology (Fig. 2B) with the amino-term- 
inal region of two native isoallergens, Par j 1A and Par j 1B, 
isolated by monoclonal antibody-based affinity chromatogra- 
phy and partially sequenced [5]. 
In order to achieve characterization at the molecular and 
immunological levels, the cDNA of the P2 clone after PCR 
was cloned without the putative signal peptide in the pMALc2 
expression vector, giving a fused protein with a molecular 
mass of approx. 53 kDa. rPar j 2.0101 expressed as a protein 
fused to maltose binding protein (MBP), was capable of bind- 
ing specifically the IgE from sera of patients allergic to P. 
judaica pollen, as shown by Western blot analysis (Fig. 3). 
The allergologic relevance of the recombinant Par j 2.0101 
was determined by slot-blot analysis [11] using single sera 
(n = 28) from patients allergic to Pj pollen with a high level 
(RAST class 4+) of specific IgE. 82% (23/28 sera) of the sera 
showed IgE capable of binding the recombinant allergen Par j 
2.0101, therefore+ it can be classified as a major allergen (data 
not shown). 
In order to assess the allergenic ross-reactivity between the 
recombinant allergens Par j 2.0101 and Par j 1.0101, the pro- 
teins were spotted on nitrocellulose membranes and incubated 
with a pool of 23 sera from Pj-allergic patients. Preincubation 
of the serum pool with increasing amounts of rPar j 2.0101 or 
rPar j 1.0101 completely abolished specific IgE binding to the 
same allergen without interference with the other and the 
results demonstrated in Fig. 4 strongly suggested that the 
two allergens howed a different IgE epitope composition. 
The recombinant allergen Par j 2.0101 was capable of in- 
hibiting approx. 35°/,, of specific IgE binding to the 10-14 kDa 
native allergens group (Fig. 5). When preincubation of the 
serum pool was performed with both the recombinant Par j 
2.0101 and Par j 1.0101, the binding of IgE to the 10 14 kDa 
native allergen region was totally inhibited, strongly suggest- 
ing that only those two allergens contributed to that region 
and that together they were capable of inhibiting the majority 
of the IgE specific for Pj allergens (Fig. 5). 
Several isoforms of the major allergen Par j 1.0101 have 
been isolated and characterized (manuscript in preparation), 
while work is actually in progress in order to isolate isoforms 
for Par j 2.0101 as well. 
Finally, a search made at the EMBL data bank showed that 
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Fig. 5. Western blotting inhibition. The Pj pollen crude extract (5 
~tg/lane) was separated on 16% PAGE-SDS and immunoblotted as
described in Section 2. Markers (Bio-Rad) expressed in kDa are 
shown on the left. Lanes: 1, serum pool preincubated with buffer 
alone as a control; 2, serum pool preincubated with 50 l.tg/ml of 
rPar j 2.0101 ; 3, serum pool preincubated with 50 Ixg/ml of rPar j 
1.0101; 4, serum pool preincubated with 50 /.tg/ml of rPar j 
2.0101+rPar j 1.0101. The inhibition procedure and IgE binding de- 
tection were performed as described in Figs. 3 and 4. 
the recombinant allergen rPar j 2.0101 belongs to a family of 
protein referred to as non-specific lipid transfer protein (ns- 
LTPs) [12,13]. These proteins constitute a broad family cap- 
able of transferring lipid molecules through membranes. 
In conclusion, in the present paper we have described the 
cloning and sequencing of a new allergen amed Par j 2.0101. 
It is a major allergen since it was found to be capable of 
interacting with IgE of 82% of the Pj-allergic sera tested. 
Regarding the already cloned major Pj allergen rPar j 
1.0101, rPar j 2.0101 is a different allergenic protein for the 
reason that it showed a different amino acid sequence and 
because there was no evident competition between the two 
recombinant allergens. 
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